Blueprint Medicines | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Blueprint Medicines

An SI Board Since April 2017

Posts	SubjectMarks	Bans	Symbol
12	15	0	BPMC

Emcee: tuck	Type: Unmoderated

Introduction Market Data Compact

Several biofreaks have pitched this company to me, and it's certainly off to a good start. They focus exclusively on kinase inhibitors for oncology and other "genomically defined" diseases, usually targeting populations subsets with a specific mutation. This approach aims at a smaller market with a higher chance of success, and is likely the best paradigm for biotechs to follow as we understand that cancer (in particular) is actually hundreds of different diseases.

They claim proof of concept in hepatocellular carcinoma, and in GIST. Indeed, their results in GIST were spectacular for a Phase 1 study. Everything is early stage, especially their partnered programs. They've not been shy about taking advantage of the market reaction to good results by financing, and they should be good for a couple of years on that front.

Here's the pipe chart: Blueprint Pipe

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
12	Thanks Tuck! A couple of things I'm wondering... Will they design the P2 f	atticus4paws	-	12/3/2018
11	Avapritinib in SM at ASH: >>Dec 02,2018 Blueprint Medicines Announce	tuck	-	12/3/2018
10	Does BPMC have any shot at 2nd line? Just to be clear, meaning any shot in KIT m	tuck	-	11/16/2018
9	Recall that in 2nd line GIST, BPMC will have to use ctDNA to find the subset for	tuck	-	11/16/2018
8	"kick me when I'm down" file, dcph completes enrollment in ph III	scaram(o)uche	-	11/15/2018
7	I'm in a similar situation here. The SM franchise still looks good, but we	tuck	-	11/15/2018
6	A week or so ago we got some results in SM that looked good to my untrained eye.	atticus4paws	-	11/15/2018
5	GIST update, data kind of meh, particularly in 4L, where PFS has really dropped	tuck	-	11/15/2018
4	>> a pretty modest one << Yes!! Intelligent, good sense of humor,	scaram(o)uche	-	11/14/2018
3	hmmmmm...... you have great powers...... first post in the thread, and yet	scaram(o)uche	-	11/14/2018
2	But tomorrow we have a bigger event, presentation of updated GIST data at CTOS.	tuck	-	11/14/2018
1	Blueprint should update this program in Systemic Mastocytosis with ~5 months mor	tuck	-	11/14/2018

Go to reply# or date (mm/dd/yy):